Premium
HCV infection and its clinical features in recipients of blood screened for HCV (C100‐3) antibody
Author(s) -
ITO SUSUMU,
HONDA HIROHITO,
HIBINO SHINGO,
NII CHIYO,
KAMAMURA MASAKO,
NISHIKADO TOMOKO,
FUJIKAWA HARUNOBU,
SAIJO TETSUYA,
OKAMURA SEISUKE,
SHIMIZU ICHIRO
Publication year - 1994
Publication title -
journal of gastroenterology and hepatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.214
H-Index - 130
eISSN - 1440-1746
pISSN - 0815-9319
DOI - 10.1111/j.1440-1746.1994.tb01210.x
Subject(s) - medicine , hepatitis c virus , antibody , hepatitis c , gastroenterology , hepacivirus , virology , immunology , virus
After adoption of the anti‐hepatitis C virus (C100‐3) test, the incidences of definite and suspected cases of post‐transfusional hepatitis (PTH) were 3.3% (7/209) and 7.2% (15/209), respectively. Four patients with definite PTH and seven patients with suspected PTH became positive for hepatitis C virus (HCV)‐related antibodies or HCV‐RNA after transfusion. These cases that became positive for anti‐HCV or HCV‐RNA showed a peak of alanine aminotransferase (ALT) more than 4 weeks after operation. Only rare cases that showed ALT peaks within 4 weeks after operation became positive for HCV‐related antibodies or HCV‐RNA. The peak ALT levels in cases showing positive conversion tended to be higher than those in cases showing no conversion. Judging from these results, cases of suspected PTH include those of transient liver disease attributable to surgery as well as clear cases of HCV infection. Thus new diagnostic criteria are required including data on HCV antibodies or HCV‐RNA.